Sorrento Therapeutics, Inc.

Equities

SRNEQ

US83587F2020

Biotechnology & Medical Research

Market Closed - OTC Markets 03:56:17 2024-03-28 pm EDT 5-day change 1st Jan Change
0.008 USD 0.00% Intraday chart for Sorrento Therapeutics, Inc. -60.00% -93.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET DJ
Final DIP Financing Approved for Sorrento Therapeutics, Inc. CI
News Highlights : Top Company News of the Day - Monday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET DJ
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc. CI
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc. CI
Interim DIP Financing Approved for Sorrento Therapeutics, Inc. CI
Health Care Slips on Growth Doubts -- Health Care Roundup DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 11 AM ET DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 7 AM ET DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 12 AM ET DJ
News Highlights : Top Financial Services News of the Day - Tuesday at 4 PM ET DJ
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc. CI
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc. CI
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc. CI
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc. CI
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90 CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million. CI
Chart Sorrento Therapeutics, Inc.
More charts
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company's immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Sorrento Therapeutics, Inc. - OTC Markets
  4. News Sorrento Therapeutics, Inc.
  5. Sorrento Therapeutics : Enters Binding Term Sheet to License Dyadic's C1 Technology for Development of Coronavirus Vaccines, Therapeutics